Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1 by Newman, Rebecca et al.
 
 
Maintenance of the marginal-zone B cell
compartment specifically requires the RNA-binding
protein ZFP36L1
Newman, Rebecca; Ahlfors, Helena; Saveliev, Alexander; Galloway, Alison; Hodson, Daniel
J; Williams, Robert; Besra, Gurdyal; Jones, Charlotte; Cunningham, Adam; Bell, Sarah E;
Turner, Martin
DOI:
10.1038/ni.3724
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Newman, R, Ahlfors, H, Saveliev, A, Galloway, A, Hodson, DJ, Williams, R, Besra, GS, Cook, CN, Cunningham,
AF, Bell, SE & Turner, M 2017, 'Maintenance of the marginal-zone B cell compartment specifically requires the
RNA-binding protein ZFP36L1', Nature Immunology. https://doi.org/10.1038/ni.3724
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
The RNA Binding Protein ZFP36L1 Maintains Marginal Zone B cells 
Rebecca Newman1,2, Helena Ahlfors1, Alexander Saveliev1, Alison Galloway1, Daniel J 
Hodson3, Robert Williams1, Charlotte N Cook4, Adam F Cunningham4, Sarah E Bell1, Martin 
Turner1* 
 
AFFILIATIONS 
1Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Babraham 
Research Campus, Cambridge, CB22 3AT, United Kingdom. 
2 Immune Receptor Activation Laboratory, The Francis Crick Institute, 1 Midland Road, 
London, NW1 1AT, United Kingdom. 
3Department of Haematology, University of Cambridge, The Clifford Allbutt Building, 
Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0AH, United Kingdom. 
4MRC Centre for Immune Regulation, School of Immunity and Infection, University of 
Birmingham, Birmingham, B15 2TT, United Kingdom. 
 
CONTACT INFORMATION 
martin.turner@babraham.ac.uk 
 
ADDITIONAL TITLE PAGE FOOTNOTES 
Role of Zfp36l1 in MZ B cells 
  
2 
Abstract  
RNA binding proteins (RBP) of the ZFP36 family are best known for inhibiting the expression 
of cytokines through binding to AU rich elements in the 3’UTR and promoting mRNA decay.  
Here we show an indispensible role for ZFP36L1 as the regulator of a post-transcriptional hub 
that determines the identity of Marginal Zone (MZ) B cells promoting their proper localization 
and survival.  ZFP36L1 controls a gene expression program related to signaling, cell-adhesion 
and locomotion, in part, by limiting the expression of the transcription factors KLF-2 and IRF-
8 that are known to enforce the follicular B cell phenotype.  These mechanisms emphasize 
the importance of integrating transcriptional and post-transcriptional processes by RBP for 
maintaining cellular identity between closely related cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Introduction 
Marginal zone (MZ) B cells surround the B cell follicles of the spleen and are continuously 
exposed to blood-borne antigens.  This positioning of MZ B cells enables them to provide 
immune surveillance of the circulatory system, and shuttle antigen to FDCs (follicular dendritic 
cells)1, 2.  Their localization to the MZ and characteristic migratory potential, to and from the B 
cell follicle, also contributes to their maintenance through the provision of survival signals 2, 3, 
4, 5.  The low activation threshold of MZ B cells enables an immediate antibody response prior 
to the production of high-affinity antibody.  Upon antigen encounter, MZ B cells are poised to 
promote T cell activation by presenting antigen as well as differentiating into plasmablasts6.  
Compared to follicular (FO) B cells, MZ B cells express greater amounts of surface IgM, CD35, 
CD21 and CD1d.  Together with elevated expression of toll-like receptors (TLR) these features 
facilitate rapid responses against blood-borne pathogens such as encapsulated bacteria7, 8.   
 
MZ B cells develop from transitional-2 (T2) B cells via an intermediary population of marginal 
zone precursor (MZP) B cells which display high cell surface expression of the complement 
receptors CD35 (CR1) and CD21 (CR2) and IgM, whilst retaining some hallmarks of 
immaturity, including expression of CD939.  Selection into the MZ B cell lineage is dependent 
upon signaling by membrane immunoglobulin, and by NOTCH2 and the BAFF-R7 9.  MZ and 
FO B cells can be separated on the basis of their gene expression profiles10, and the 
differences in their transcriptomes contribute to the differential development, localization and 
function of these cells.  Consistent with this, transcriptional regulators have been shown to 
have specific roles in MZ and FO B cells.  Of these, NOTCH2 plays a gene dose-dependent 
and non-redundant role in promoting the MZ B cell fate11, 12, and signaling through the 
NOTCH2 receptor is essential for the retention of B cells in the MZ4.  Interferon Regulatory 
Factor (IRF)-4, and the related IRF-8 limit the size of MZ B cell pool13, and IRF-4 regulates the 
positioning of cells in the MZ by restricting NOTCH2 function.  Krüppel-like factor (KLF)-2 
enforces the FO B cell phenotype.  In its absence, the MZ B cell pool is expanded and FO B 
cells show the signaling and migration characteristics of MZ B cells14, 15.  By contrast, KLF3 
promotes the persistence of MZ B cells and may antagonise the activity of KLF216.  These 
factors are frequently mutated in splenic MZ lymphoma17, suggesting they may also form part 
of a network that sustains the survival and localization of MZ B cells in pathological situations.  
Thus the interrelationship between transcriptional regulation, signal transduction and cell 
positioning for the development and survival of MZ B cells needs to be further understood17.  
Despite this, central regulators of this network have yet to be described. 
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The post-transcriptional control of RNA is a mechanism of gene regulation that brings about 
changes in the transcriptome through alterations in RNA processing and stability; it also 
regulates the proteome through changes in the tempo or location of mRNA translation.  These 
versatile mechanisms, which are directly regulated by RNA binding proteins (RBP), as well as 
non coding RNAs, complement transcriptional control and add robustness to gene regulatory 
networks18.  Profiling of microRNAs indicated that, when compared to FO B cells, MZ B cells 
contained fewer microRNAs, and deletion of Dicer19, or microRNA-14220, led to increased 
proportions of B cells with a MZ phenotype, suggesting in aggregate that microRNAs suppress 
MZ formation or survival.  Deletion of the well-studied RBPs AUF121 or Elavl1 (HuR)22 in B 
cells had no effect on MZ numbers.  By contrast, retroviral expression of lin28b, acting in 
haematopoietic stem cells, promoted the development of MZ B cells23, 24.  Thus the essential 
post-transcriptional mechanisms governing MZ B cell biology remain to be fully elucidated. 
 
Amongst the more than 1500 RBP in the mammalian genome, the ZFP36 family are 
characterised by the presence of two highly conserved CCCH-type zinc fingers, which bind 
RNA.  By interacting with Adenosine-uridine-Rich Elements (AREs) in the 3’UTR of mRNAs 
these RBP promote RNA instability and are an important link between the transcriptome and 
the proteome25.  ZFP36 (TTP, Tis11, Nup475, G0S24) has been best characterised as a 
suppressor of cytokine production in innate immune cells; its relatives ZFP36L1 (Tis11b, 
BRF1, BERG36, ERF-1) and ZFP36L2 (Tis11d, BRF2, ERF-2) have been shown to play a 
redundant role during T and B lymphocyte development26, 27.  The roles of the ZFP36 family 
during the development and maintenance of mature B-lymphocytes has not been studied.  
Here we demonstrate the indispensible role of ZFP36L1 in the maintenance of MZ B cells.  
Through comprehensive analysis of the transcriptomes of primary mouse B cells, and the 
identification of ZFP36L1 targets in B cells by individual-nucleotide resolution Cross-Linking 
and Immunoprecipitation (iCLIP), we identify the direct and indirect targets of ZFP36L1 in B 
cells, and determine a network of factors under the control of ZFP36L1 that sustains MZ B 
cells.  This study demonstrates that cellular identity and ultimately survival is determined by 
an RNA binding protein.    
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Results  
MZ B cells specifically require ZFP36L1 
To identify the roles of the ZFP36 family during lymphocyte development we made use of 
hCD2-icre, which deletes in early lymphoid progenitors28, to generate mouse models that are 
conditionally deficient for Zfp36 (Supplementary Fig. 1), Zfp36l1 or Zfp36l226.  MZ B cells 
were reduced nine-fold following lymphocyte specific deletion of Zfp36l1 while MZ B cell 
numbers were normal in mice with a lymphocyte specific deficiency of Zfp36 or Zfp36l2 (Fig. 
1a).  In all three models FO B cell numbers were not substantially different from littermate 
control mice (Fig. 1b).  Transcripts encoding all three ZFP36 family members are expressed 
in MZ cells from C57BL/6 mice (Fig. 1c), indicating that the specific requirement for ZFP36L1 
is not due to cell-specific mRNA expression.  Thus, there is a role for ZFP36L1 in the 
development or maintenance of MZ B cells that cannot be compensated for by ZFP36 or 
ZFP36L2. 
 
B cell intrinsic requirement for ZFP36L1 
Deletion of Zfp36l1 at the pro-B cell stage, using mb1cre, also led to a loss of MZ B cells (data 
not shown).  To confirm the requirement of ZFP36L1 independently of a role in the bone 
marrow stages of early B cell development, we generated mice in which Zfp36l1 is deleted at 
the T2 B cell stage under the control of CD23cre29.  In these mice we observed a 10-fold 
reduction in the number of MZ B cells (Fig. 2a, b) and a two-fold reduction in the number of 
MZP B cells (Fig. 2d, e).  Peritoneal cavity B cell numbers were also analysed in 
Zfp36l1fl/flmb1cre/+ and Zfp36l1fl/fl control mice.  We observed a small but significant 4-fold 
decrease in total B1 cells upon Zfp36l1 deletion with B1a cells and B1b cells equally affected 
(Supplementary Fig. 2a-f).  B2 cell numbers in the peritoneal cavity were not different 
between Zfp36l1fl/flmb1cre/+ and Zfp36l1fl/fl control mice (Supplementary Fig. a, c).  This small 
effect on B1 cell numbers contrasts with the much larger effect on MZ B cell numbers 
 
To further understand the role of ZFP36L1 in mature B cells we conditionally expressed a 
GFP-ZFP36L1 fusion protein27 using CD23cre.  In Rosa26GFPZFP36L1CD23cre/+ mice GFP-
ZFP36L1 expression is evident from the T2 B cell stage (Supplementary Fig. 2g).  
Rosa26GFPZFP36L1CD23cre/+ mice have a 1.5-fold expanded MZ B cell population, but there are 
no effects on the numbers of FO B cells and MZP B cells (Fig. 2f-j).  Examination of MZ B 
cells by immunofluorescence staining of spleen sections confirms they are much reduced in 
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number in Zfp36l1fl/flCD23cre/+ mice and expanded in Rosa26GFPZFP36L1CD23cre/+ mice (Fig. 2k, 
l).  This demonstrates an intrinsic requirement for ZFP36L1 from the T2 B cell stage for the 
development and/or maintenance of MZ B cells and their precursors.  
 
 
ZFP36L1 is selectively required for the maintenance of MZ and MZP B cells 
To test the continued requirement for ZFP36L1 in B cells we used a cre-oestrogen receptor 
fusion (ERT2) transgenic in which cre activity is elicited by tamoxifen.  As Zfp36l1 is deleted 
subsequent to development, a role for this RBP in sustaining MZ B cells can be established.  
At seven days following tamoxifen treatment, Zfp36l1flox was efficiently recombined at the DNA 
level, and MZ B cell numbers were decreased by 1.3-fold (Supplementary Fig. 3a-c).  
Recombination efficiency of Zfp36l1 remained high at later time-points, and by day 10 MZ B 
cells were further decreased by 1.7-fold; and by day 14 a 3.2-fold reduction in number was 
observed (Supplementary Fig. 3d-i).  This on-going depletion was selective for MZ B cells 
as FO B cell numbers were not different at any of the three time-points tested.  To exclude 
that this effect was due to roles of Zfp36l1 in non-haematopoietic cells30, 31, we reconstituted 
irradiated B6.SJL mice with bone marrow from Zfp36l1fl/flERT2cre/+ mice, and ERT2cre/+ bone 
marrow as a control group, prior to the administration of tamoxifen (Fig. 3a).  In this system, 
Zfp36l1 deletion is efficient in B cells following tamoxifen treatment (Fig. 3b).  In the chimeras 
reconstituted with Zfp36l1fl/flERT2cre/+ bone marrow there was a selective loss of MZ and MZP 
B cells following treatment with tamoxifen (Fig. 3c, d), whilst FO and transitional B cell subsets 
remained unchanged in number compared to the ERT2cre/+-only control chimeras (Fig. 3e; 
data not shown).  Therefore Zfp36l1 is dispensable for the maintenance of FO B cells but 
necessary for the persistence of MZ and MZP B cells.  
To address whether the absence of ZFP36L1 affected cell survival we measured the presence 
of active caspase-3 by flow cytometry in B cells from these chimeras.  An increased proportion 
of Zfp36l1-deficient MZ B cells but not FO B cells were positive for active caspase-3 and thus 
undergoing apoptosis (Fig. 3f, g).  The same effect was seen in mice that are conditionally 
deficient for the RBP (Fig. 3h, i).  By feeding Zfp36l1fl/flmb1cre/+ mice 2-bromodeoxyuridine 
(BrdU) in their drinking water we assessed the turnover of MZ B cells measuring the presence 
of BrdU labelled cells.  During B cell development, BrdU is primarily incorporated into highly 
proliferative pre-B cells in the bone marrow.  In Zfp36l1fl/flmb1cre/+ mice we observe no change 
in the entry of BrdU-labeled cells into the FO B cell pool but increased labeling of MZ B cells, 
and a small decrease of BrdU positive T2 and MZP B cells (Fig. 3j; Supplementary Fig. 4a).  
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This is consistent with the increased turnover of MZ B cells.  By contrast, in the mice 
expressing GFP-ZFP36L1 (Rosa26GFPZFP36L1CD23cre/+) BrdU incorporation was decreased in 
MZ B cells and slightly increased in the T2 and MZP B cells compared to the controls (Fig. 
3k; Supplementary Fig. 4b).  Thus MZ B cells turn over more slowly when they express GFP-
ZFP36L1.  Taken together these data indicate that ZFP36L1 promotes the survival of MZ B 
cells but is dispensable for the survival of FO B cells. 
 
Gene expression changes following inducible deletion of Zfp36l1 
As Zfp36l1 controls gene expression by promoting RNA decay25, 27, its direct targets will be a 
subset of those RNAs that show increased expression in mutant cells.  To identify these we 
first performed RNAseq on sorted MZ B cells from tamoxifen treated Zfp36l1fl/flERT2cre/+ and 
ERT2cre mice.  The elective deletion of Zfp36l1 was efficient as we observed a significant 
decrease in the number of reads mapped within the floxed region of the gene, and most of the 
remaining reads were found to map to exon 1 that lies outside of the floxed region 
(Supplementary Fig. 5a).  Upon loss of Zfp36l1 we observed significant (padj<0.01) 
increases in the expression of 330 transcripts and diminished expression of 215 transcripts.  
Of these, 84 and 26 transcripts were increased or decreased in expression by greater than 
1.5 fold respectively (Fig. 4a; Supplementary table 1).  The 50 transcripts that showed the 
greatest changes in expression are illustrated as a heatmap in supplementary figure 5.  We 
observed an increase in the expression of Zfp36l2 (Fig. 4a; Supplementary Fig. 5b), further 
indicating that ZFP36L2 cannot compensate for ZFP36L1 in MZ B cells.  
The direct targets and the specific nucleotide contacts between ZFP36L1 and RNAs can be 
identified by iCLIP, but this method has a requirement for large numbers of cells and it is not 
sensitive enough to apply to MZ B cells.  Nevertheless, we attempted to identify ZFP36L1 
targets by making use of ZFP36L1 iCLIP data from activated FO B cells27.  Although the iCLIP 
has not been performed on MZ B cells it identifies candidate mRNAs that can be bound by 
ZFP36L1.  Thus 73 genes with increased expression, 11 of which were increased by a fold 
change of greater than 1.5 (Fig. 4b; Supplementary table 2, 3), are identified as possible 
direct targets of ZFP36L1 in MZ B cells.  24 transcripts with diminished expression in MZ B 
cells were also found to overlap with the iCLIP data, however only a single transcript (Per2) 
exhibited a fold change of greater than 1.5 fold, suggesting that the iCLIP data is a stringent 
criterion for identifying direct targets of ZFP36L1 in MZ B cells (Fig. 4b).  
To identify the functional roles of the differentially expressed genes in Zfp36l1-deleted MZ B 
cells we performed a gene set enrichment analysis (GSEA) on all genes that were significantly 
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altered (padj<0.01) (Supplementary table 2, 3).  A number of genes found to be differentially 
expressed were recurrent within distinct GSEA pathways leading to overrepresentation of 
redundant GO terms.  We therefore summarised our GSEA analysis using Revigo to 
consolidate overlapping GO terms.  This way of visualizing the data indicated that there were 
a substantial number of differentially expressed transcripts involved in signaling; cellular 
adhesion and migration; the cell cycle and proliferation; and programmed cell death (Fig. 4c).  
Those transcripts that were expressed at reduced amounts did not comprise any common 
pathway or gene set, which suggests that these genes do not have a common functional role 
in MZ B cells.  
We recently reported evidence of a role for the ZFP36 family of RBP in promoting 
quiescence27, 32.  In Zfp36l1-deficient MZ B cells, the mRNAs encoding Ccna2, E2f2, Cdc6, 
Pim1, Ccnd3 and Cdk1 were ≥1.5 fold increased (Fig. 4c; Supplementary table 1, 2).  To 
assess whether this had any functional consequences for MZ B cells, we analysed the 
proportion of MZ B cells expressing the cyclin-dependent kinase inhibitor p27KIP1 (Cdkn1b) a 
marker of quiescent cells.  The expression of p27 in MZ B cells, and the proportion of p27 
positive MZ B cells from tamoxifen-treated Zfp36l1fl/flERT2cre/+ mice were unchanged when 
compared to littermate controls (Supplementary Fig. 7a-c), suggesting quiescence was 
actively maintained.  Furthermore, the results of Ki67 and DAPI staining were consistent with 
this conclusion (Supplementary Fig. 7d-i).  Thus the reduction of MZ B cells following 
developmentally programmed or induced deletion of Zfp36l1 was not due to a loss of 
quiescence. 
 
ZFP36L1 enforces MZ B cell identity 
To further understand the changes in the MZ B cell transcriptome arising from deletion of 
Zfp36l1 we compared transcripts that were differentially expressed between Zfp36l1-deficient 
and Zfp36l1-sufficient MZ B cells with those that were differentially expressed between 
wildtype MZ and FO B cells.  This revealed that two thirds of the transcripts (54) with the 
greatest increase in expression in Zfp36l1-deficient MZ B cells are normally more highly 
expressed in FO B cells than in MZ B cells (Fig. 5a; Supplementary table 4).  This did not 
reflect contamination of the sorted KO MZ B cells with FO B cells because only a subset of 
FO B cell enriched transcripts were increased in expression.  Some transcripts, which are 
normally more highly expressed by MZ than FO B cells, (such as PlexinD1 and c-Myc) were 
also increased in the KO MZ B cells.  The differentially expressed transcripts have roles in B 
cell trafficking, signal transduction and the cell division cycle.  Thus in the absence of Zfp36l1 
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the remaining MZ B cells show increased expression of transcripts associated with the FO B 
cell phenotype.   
 
To determine the effect of GFP-ZFP36L1 on the transcriptome of FO B cells we performed 
RNAseq and compared the transcriptomes of GFP-ZFP36L1 expressing FO B cells to FO B 
cells from littermate controls.  Pairwise comparison with genes differentially expressed 
between FO and MZ B cells indicated a trend for GFP-ZFP36L1 positive FO B cells to have 
increased expression of genes that are preferentially expressed in MZ B cells (Fig. 5b, top 
right hand quadrant; Supplementary table 5) and reduced expression of genes 
characteristically expressed in FO B cells (Fig. 5b, bottom right hand quadrant; 
Supplementary table 5).  A negative correlation (R=-0.42 of log2FoldChange values) was 
evident between differentially expressed genes in FO B cells expressing GFP-ZFP36L1 and 
differentially expressed genes following the loss of ZFP36L1 in MZ B cells (Fig. 5c).  
Transcripts that are increased in Zfp36l1-deficient MZ B cells are typically those that are 
decreased in GFP-ZFP36L1-expressing FO B cells (116 highlighted in red, top left quadrant; 
Supplementary table 6).  Moreover, transcripts that are increased in GFP-ZFP36L1-
expressing FO B cells are typical of MZ B cells (84 highlighted in red, bottom right quadrant; 
Supplementary table 6).  This supports the hypothesis that ZFP36L1 is required to maintain 
MZ B cell identity.   
We next examined cell surface markers expressed by FO B cells from 
Rosa26GFPZFP36L1CD23cre/+ mice.  GFP-ZFP36L1 expressing FO B cells showed increased 
expression of CD21, CD1d and MHCII (Fig. 5d), indicating that their surface phenotype and 
“activation” status resembled MZ B cells.  Furthermore, immunofluorescence of spleen 
sections showed increased CD1d+ cells, which also express IgD, residing within the follicle of 
Rosa26GFPZFP36L1 CD23cre/+ mice compared to controls (Fig. 2k; Supplementary Fig. 8a white 
arrowheads).  As a number of the differentially expressed transcripts we identified had roles 
in cell signaling we measured calcium flux elicited by surface IgM crosslinking in Zfp36l1-
deficient MZ B cells.  Enhanced BCR elicited calcium flux is a hallmark of the MZ phenotype 
compared to FO B cells33 and we observed this phenomenon in control littermate mice (Fig. 
5e, f).  However, calcium flux was reduced in Zfp36l1-deficient MZ B cells to the level of FO B 
cells (Fig. 5e), but was not altered in Zfp36l1-deficient transitional B cell subsets (data not 
shown) or FO B cells (Fig. 5e).  Pre-treatment with EGTA, to chelate extracellular calcium, 
reveals the defective release of calcium from the internal stores of Zfp36l1-deficient MZ B cells 
(Fig. 5f).  Thus one role of ZFP36L1 in MZ B cells is to enhance BCR signaling.  Taken 
together, these data suggest that ZFP36L1 enforces the phenotype of MZ B cells.  To test for 
10 
functional defects of the residual MZ B cells, we immunized Zfp36l1fl/flCD23cre/+, 
Rosa26GFPZFP36L1 CD23cre/+ and littermate control mice with the CD1d-restricted antigen NP-α-
GalCer34. NP-specific antibody titres from sera taken at day-4 post immunization produced are 
not different when comparing Zfp36l1fl/flCD23cre/+ and Zfp36l1fl/fl control mice, indicating MZ B 
cell numbers in the knockout are not limiting in the response of MZ B cells to antigen in vivo 
(Supplementary Fig. 8b).  There was a small increase in serum NP-IgM in mice expressing 
the GFP-ZFP36L1 fusion protein, which may reflect increased numbers of MZ B cells in these 
mice. Overall this data indicates little evidence for a role of ZFP36L1 in the response of MZ B 
cells to antigen in vivo/CD1d restricted humoral responses in vivo.    
 
ZFP36L1 targets transcription factors important for MZ B cell identity and survival 
IRF8 mRNA was increased 1.3-fold (padj<0.0002) in MZ B cells in the absence of ZFP36L1 
(Fig. 6a), and was decreased in expression in GFP-ZFP36L1-positive FO B cells (Fig. 6b).  
IRF8 protein expression was also elevated in ZFP36l1-deficient MZ B cells (Fig. 6c, d).  Irf8 
mRNA contains a highly conserved ARE in its 3’UTR and was bound by ZFP36L1 in the iCLIP 
assay (Fig. 6e), indicating it is a likely direct target of ZFP36L1 in MZ B cells.  A role for IRF8 
in limiting MZ B cell numbers is suggested by data showing loss of IRF8 leads to an enlarged 
MZ B cell compartment13.  To assess whether IRF8 target genes are likely to contribute to the 
observed MZ phenotype, we determined if the differentially expressed transcripts in our 
RNAseq data from Zfp36l1-deficient MZ B cells were also identified as IRF8 targets in high 
quality ChIP-seq data35.  This indicated that a subset of “FO-signature” genes expressed by 
Zfp36l1-deficient MZ B cells are bound by IRF8 (Fig. 6f), suggesting that increased expression 
of IRF8 contributes directly to the altered expression of these genes in the absence of 
ZFP36L1.  By assessing the distribution of direct ZFP36L1 targets identified by the iCLIP and 
IRF8 target genes amongst differentially expressed transcripts, we observed minimal overlap 
of the majority of ZFP36L1 targets (shown in black in Fig. 6g) with highly differentially 
expressed IRF8 targets (shown in dark green, Fig. 6f).  This indicates that ZFP36L1 and IRF8 
generally act in a hierarchical manner whereby ZFP36L1 targets a range of genes including 
IRF8, which in turn targets genes important for cell survival, localisation, signaling and MZ B 
cell identity.  
 
KLF2 mRNA was 3.1 fold increased in Zfp36l1-deficient MZ B cells (Fig. 4a; 7a).  KLF2 protein 
was also increased in Zfp36l1-deficient MZ B cells as assessed by flow cytometry (Fig. 7b, c).  
Klf2 mRNA contains a TATTTATT ARE in its 3’UTR, which is conserved amongst mammalian 
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species that have a Klf2 ortholog (Fig. 7d; Supplementary table 2).  The binding of ZFP36L1 
to this ARE was indicated in our iCLIP analysis (Fig. 7d); however the binding did not reach 
statistical significance due to low KLF2 mRNA abundance in activated B cells15, 36.  Thus, 
ZFP36L1 may directly limit expression of KLF2.  Mice with KLF2-deficient B cells have a five-
fold increase in the number of MZ B cells, and the FO B cells from these mice express 
increased amounts of a number of genes that are characteristic of MZ B cells14, 15 indicating 
that KLF2 suppresses a gene expression programme which underpins the MZ B cell 
phenotype.   
 
To understand if elevated KLF2 expression contributed to the altered gene expression profile 
of Zfp36l1-deficient MZ B cells we combined ChIPseq data37 with a microarray analysis of 
Klf2-deficient B cells14 to generate a list of candidate KLF2 target genes that are relevant to B 
cells.  Next, this gene list was used to identify candidate KLF2 target genes in our 
transcriptome analysis from wild-type FO and MZ B cells and Zfp36l1-deficient MZ B cells.  
This approach identified a subset of genes that are bound by KLF2; expressed at elevated 
levels in Zfp36l1-deficient MZ B cells; and normally more highly expressed in FO B cells than 
in MZ B cells (shown in dark blue) (Fig. 7e).  Furthermore, this analysis showed that among 
the transcripts increased in Zfp36l1-deficient MZ B cells the KLF2-regulated genes are 
generally absent from both the ZFP36L1 iCLIP dataset and the IRF8 ChIPseq dataset (Fig. 
7f).  This indicates that the observed KLF2 overexpression is consequential for the 
transcriptome of Zfp36l1-deficient MZ B cells and that KLF2 contributes directly to the 
manifestation of a “FO-signature” transcriptome in Zfp36l1-deficient MZ B cells.  Taken 
together, these analyses suggest a model whereby ZFP36L1 limits the expression of a number 
of genes including the transcription factors IRF8 and KLF2, which in turn regulate genes 
important for MZ B cell identity and survival (Supplementary Fig. 8c).   
 
ZFP36L1 deficiency results in aberrant trafficking and distribution of B cells 
By performing GSEA on 116 transcripts that were both increased in expression in MZ B cells 
following deletion of Zfp36l1 and decreased in expression in FO B cells expressing GFP-
ZFP36L1 (Supplementary Fig. 9a) we identified pathways involved in B cell trafficking; 
highlighted in red in Supplementary Fig. 9b.  Flow cytometry analysis demonstrated that 
there was increased expression of CD62L and β7 integrin on the cell surface of Zfp36l1-
deficient MZ B cells and decreased expression of these on GFP-ZFP36L1 positive FO B cells 
(Fig. 8a).  We observed little, if any, difference in the expression of CXCR4, CXCR5, β1 integrin 
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and LFA-1 (data not shown).  Consistent with our RNAseq results (Supplementary Fig. 9c), 
we saw no difference in the expression of CD69 (a surrogate marker for S1Pr1 expression) 
(Fig. 8a).  To assess whether the localisation of MZ B cells was altered in the absence of 
ZFP36L1, we tested the ability MZ B cells to capture CD19-PE from the blood in 
Zfp36l1fl/flCD23cre/+ mice.  This showed a decreased proportion of CD19-PE positive MZ B cells 
in the absence of ZFP36L1, suggesting an abnormal localization and/or trafficking of Zfp36l1-
deficient MZ B cells in vivo (Fig. 8b).   
Immunofluorescence analysis of spleen sections from μMT chimeras with tamoxifen-deleted 
Zfp36l1 indicated that an increased proportion of CD1d+ MZ B cells were localized in the 
splenic follicles (Fig. 8c).  Importantly, these CD1d+ cells do not co-express IgD 
(Supplementary Fig. 8a white arrowheads).  Quantification of CD1d expression within the 
splenic follicles (defined by MOMA-1 staining, see Supplementary Fig. 9e) demonstrated an 
increase in the MFI when Zfp36l1 has been acutely deleted, compared to ERT2cre/+ controls 
(Fig. 8d).  To confirm that this did not result from increased CD1d expression across all cell 
types we quantified the MFI of CD1d+ cells residing in the MZ (Supplementary Fig. 9e).  This 
showed that CD1d expression was comparable between Zfp36l1fl/flERT2cre/+ and ERT2cre/+ MZ 
B cells localised within the splenic MZ (Fig. 8e).  By normalising CD1d MFI within the splenic 
follicle to overall CD1d expression in the FO and MZ, we confirmed an increased proportion 
of CD1d+ MZ reside in the follicles of Zfp36l1-deficient mice (Fig. 8f).  Thus, ZFP36L1 plays a 
role in the correct localization of MZ B cells. 
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Discussion 
Here we report the essential role for ZFP36L1 in the maintenance of MZ B cells.  The RBP 
mediates this role by interacting with, and limiting the expression of, a set of transcripts that 
promote the FO B cell phenotype.  The relevant targets of ZFP36L1 in this context are distinct 
from previously identified targets such as cytokines and drivers of cell cycle progression.  This 
observation is reminiscent of the role of transcription factors which, at discrete stages of B cell 
development, control the expression of different transcripts characteristic of that 
developmental stage38.  It further suggests that ZFP36L1 has the potential to regulate post-
transcriptional RNA operons or “regulons”39 tailored to a specific developmental stage. 
Consistent with this, ZFP36L1 has been shown to regulate the transcription factor nanog and 
contribute to differentiation in mouse embryonic stem cells40.  It can thus be anticipated that 
ZFP36L1 or its close relatives may play roles in maintaining the distinct identity of other closely 
related cell types in the immune system; a property previously thought to be exclusive to 
transcription factors.  Such a notion has precedence in other developmental biology systems.  
In Caenorhabdtis elegans the germline and somatic cell fates are regulated by multiple RBPs, 
many of which contain the tandem CCCH zinc fingers that are characteristic of the ZFP36 
family.  Amongst these, Oocyte MAturation defective-141 and POsterior Segregation-142 have 
been shown to bind with high affinity to AU-rich sequences in 3’UTRs of target mRNAs.  
Systems analysis indicates extensive crosstalk between RNA binding proteins and 
transcription factors in C. elegans43.  Our findings may reflect the existence of similar networks 
in mature B lymphocytes.  Thus the ability of RBPs to play a dominant role in directing or 
maintaining cell fates amongst additional immune cell populations by acting on 3’UTRs 
deserves further investigation.  Formally establishing this mechanism in lymphocytes will 
require both the identification of the relevant RBP, as we have done here, and demonstrating 
the necessity for sequences in 3’UTRs bound by the RBP for the maintenance of cellular 
identity. 
 
As the RNA binding domains of each ZFP36 member are highly related in sequence, and 
redundancy between co-expressed family members is frequently found, the unique role for 
Zfp36l1 that we have found here in MZ B cells, which express all three ZFP36 family members, 
was unanticipated.  The specific requirement for Zfp36l1 in B cells for the MZ B cell 
compartment may reflect differences in the post-translational biology of the encoded RBPs, 
such as the effects of specific phosphorylation or of multi-protein complex formation.  
Alternatively there may be differences between ZFP36 family members in their ability to bind 
to and regulate specific targets.  Our data indicate that the mRNA encoding the related 
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ZFP36L2, which acts redundantly with ZFP36L1 in the thymus and bone marrow, was bound 
by ZFP36L1, and the abundance of ZFP36L2 was substantially increased in ZFP36L1-null MZ 
B cells.  However, unlike the situation in early lymphocyte development, ZFP36L2 could not 
compensate for the absence of ZFP36L1 in MZ B cells.  Extensive further work is required to 
understand the molecular basis for the redundant and non-redundant functions of these RBPs. 
 
While the role of Zfp36l1 in the maintenance of MZ B cells is mediated by the repressive effects 
of this RBP on the B cell transcriptome there are a number of indirect changes in the 
transcriptome that follow from the enhanced expression of ZFP36L1 targets.  This suggests 
that the transcriptome of MZ B cells is determined by network of factors, acting transcriptionally 
and post-transcriptionally, in which ZFP36L1 is a major hub (Supplementary Fig. 8b).  Here 
we have focussed on two direct targets of ZFP36L1, identified by our iCLIP analysis, IRF8 and 
KLF2, which in turn regulate a number of downstream genes important for MZ B cell identity.  
Many, but not all, of the indirect changes in the transcriptome of Zfp36l1 deficient MZ B cells 
appeared to stem from the increased expression of IRF8 or KLF2 (these transcription factors 
account for 18/54 differentially expressed “FO signature” genes).  Many KLF2 targets, that 
were not ZFP36L1 targets, were increased following loss of Zfp36l1 and a number of these 
were also suppressed in the GFP-ZFP36L1 expressing FO B cells.  Overall the phenotype of 
Zfp36l1-deficiency in mature B cell development has similarities to that of B cells with mutated 
KLF3, a transcription factor that appears to act as a transcriptional repressor of KLF216.  
Conversely, transgenic B cells overexpressing KLF3 have a similar phenotype to GFP-
ZFP36L1 expressing B cells44.  The molecular basis for KLF2 and KLF3 regulation of 
trafficking in B cells remains relatively poorly understood, as it appears to affect responses to 
chemokines in both MZ and FO B cells as well as regulating surface expression of adhesion 
receptors45.  IRF8, like IRF44, has a role in limiting the size of the MZ B cell pool13.  Additional 
ZFP36L1 targets amongst the transcripts with increased expression need to be further 
characterised for their mechanistic roles in peripheral B cell maturation and maintenance, 
however there is evidence to link many of these to adhesion and metastasis.  The kinase Pim1 
has been implicated in loss of adhesion and altered cell migration46, 47; the transcription factor 
Bhlhe40 which has not been functionally characterised at all in B cells but is known to play a 
role in T cells where it is important for the effects of pertussis toxin48 and in other cell types 
Bhlhe40 has been implicated in adhesion and metastasis49.  Likewise KIAA0101 
(2810417H13Rik) has been associated with metastasis50.  Much less is known about Myadm 
(myeloid-associated differentiation marker) but it too has been implicated in adhesion51, 52.  
Txnrd1 (thioredoxin reductase 1) has also been implicated in adhesion and migration53, 54.  
We thus suggest that ZFP36L1 serves to coordinate the abundance of proteins that act at 
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many different stages in the cell biology of adhesion and migration.  These examples form the 
basis of a network of transcriptional and post-transcriptional interactions that “lock-in” cell 
specific transcriptomes.  There is an enhanced regulatory flexibility conferred by dual 
transcriptional and post-transcriptional control, as pathways that are under the control of 
different transcription factors may be strongly coordinated by RNA binding proteins. 
 
The small decrease in the number of MZP B cells in the spleen when B cells specifically lack 
ZFP36L1, contrasts with the phenotype of mice in which NOTCH2 signalling is attenuated 11, 
12, 55 and suggests that ZFP36L1 plays a minimal role in the development of MZ B cells but is 
primarily required for the persistence of MZ B cells in vivo.  The FO B cell pool and its precursor 
populations are intact in the absence of ZFP36L1 indicating that this RBP plays no obvious 
role in FO B cell development and/or maintenance.  As we did not observe an apoptosis gene 
expression signature in our RNAseq analysis that was regulated directly by ZFP36L1 it is likely 
that this apoptosis arises indirectly due to a loss of cellular identity and abnormal adhesion 
and migration.  The maintenance of the MZ phenotype and survival may be affected by the 
intrinsic signaling capability of membrane immunoglobulin, which was reduced in MZ B cells 
lacking ZFP36L1, and has also been linked previously to the adhesive and motile capacity of 
MZ B cells.  Some of these mechanisms are finely balanced as evidenced by their sensitivity 
to gene dosage.  Instead, the interaction between MZ B cells and unique extracellular matrix 
components that are enriched in the MZ, and play an important role in promoting the survival 
of MZ B cells3, may be perturbed.  These mechanisms protect MZ B cells from apoptosis.  It 
is therefore tempting to speculate that Zfp36l1-deficient MZ B cells are lacking these pro-
survival signals when access to the MZ is limited.  This may be analogous to the process of 
anoikis whereby detachment of adherent cells from a niche can lead to programmed cell 
death56.  
In summary, our data suggest that ZFP36L1 acts post-transcriptionally to enforce the 
phenotype of MZ B cells and in its absence MZ B cells are mislocalized and die.  It will be 
important for future studies to establish whether these mechanisms contribute to pathology in 
lymphoma or autoimmune disease. 
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FIGURE LEGENDS 
Figure 1: MZ B cells specifically require ZFP36L1 
Number of (a) MZ B cells (b) FO B cells from the spleens of ZFP36 family conditional knockout 
mice assessed by flow cytometry.  Each symbol represents data from an individual mouse.  
Data were analysed using a Mann-Whitney test.  (c) ZFP36 family relative mRNA expression 
in sorted MZ B cells.  Bars are representative of 3 biological replicates, error bars represent 
SEM. 
 
Figure 2: B cell intrinsic requirement for ZFP36L1  
Flow cytometric analysis of splenic B cells from Zfp36l1fl/flCD23cre/+ and 
Rosa26GFPZFP36L1CD23cre/+ mice.  Dot plots are pre-gated on (a, f) B220+CD93- cells (e, j) 
B220+CD93+ cells.  Numbers indicate the percentage of cells within the gate.  Data are 
representative of at least 6 mice per genotype.  Absolute number of (b, g) MZ B cells (c, h) 
FO B cells (d, i) MZP assessed by flow cytometry.  Data on all graphs were analysed using a 
Mann-Whitney test.  (k) Immunofluorescence analysis of spleen sections from 
Zfp36l1fl/flCD23cre/+ mice, Rosa26GFPZFP36L1CD23cre/+ mice and a Zfp36l1fl/fl control.  Sections 
were stained with either anti-CD1d (magenta), anti-IgD (cyan) and anti-CD169 (green) or anti-
IgM (magenta) and anti-CD169 (green).  All images were captured at 10x magnification, scale 
bars are shown.  (l) Quantification of CD1d+ MZ width.  Multiple measurements were taken 
using Image-J (NIH) from at least 10 separate follicles per genotype.  Data were analysed with 
Mann-Whitney tests. 
 
Figure 3: ZFP36L1 is selectively required for the maintenance of MZ and MZP B cells 
(a) Time course depicting generation and analysis of Zfp36l1fl/flERT2cre/+ radiation chimeras.  
(b) Relative Zfp36l1 exon 2 abundance in purified B cells assessed by qPCR in tamoxifen 
treated chimeras.  Data are representative of two independent experiments (n=6 mice per 
group in each experiment).  Numbers of (c) MZ B cells (d) MZP (e) FO assessed by flow 
cytometry in tamoxifen treated irradiation chimeras.  Data are representative of two 
independent experiments.  Data were analysed with a Mann-Whitney test.  Proportions of (f) 
MZ B cells (g) FO B cells from tamoxifen treated Zfp36l1fl/flERT2cre/+ radiation chimeras (open 
circles) and ERT2cre/+ control chimeras (closed circles) staining positive for active caspase3.  
Data were pooled from two independent experiments.  Proportions of (h) MZ B cells and (i) 
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FO B cells from Zfp36l1fl/flmb1cre/+ (open circles) and Zfp36l1fl/fl control mice (closed circles) 
staining positive for active Caspase3.  Data were pooled from two independent experiments.  
Day 14 BrdU incorporation into MZ B cells in (j) Zfp36lfl/flmb1cre/+ conditional knockout mice 
(open circles) and Zfp36l1fl/fl littermate control mice (closed circles) and (k) 
Rosa26GFPZFP36L1CD23cre/+ (open circles) and Rosa26GFPZFP36L1 littermate control mice (closed 
circles).  All statistical analysis was performed with a Mann-Whitney test. 
 
Figure 4: Gene expression analysis following deletion of Zfp36l1 
(a) MA plot showing differentially expressed transcripts in red.  Cut-off (grey dashed line) is 
1.5 fold, padj<0.01.  (b) Bar chart showing the number of differentially expressed transcripts 
(padj<0.01), which are increased or decreased in expression, indicating the number of 
transcripts that overlap with the iCLIP dataset (FDR<0.05) in blue.  (c) GSEA was carried out 
using Toppfun tool which is part of ToppGeneSuite for all differentially expressed transcripts 
(padj<0.01), and summarised using Revigo57 to remove redundant GO terms.  The remaining 
terms are visualised as a semantic similarity-based scatter plot.  Each bubble represents a 
biological process, size of the bubble represents log(number of genes in each process), and 
colour is indicative of uniqueness, where red (1) indicates exact overlap with other terms found 
in the GSEA, and blue (0.6) indicates minimal overlap with other terms found in the analysis.   
 
Figure 5: ZFP36L1 enforces MZ B cell identity 
(a) Correlation dot plot indicating the differentially expressed transcripts in red (padj<0.01) 
when comparing Zfp36l1fl/flERT2cre/+ (KO) MZ B cells and ERT2cre/+ control (WT) MZ B cells to 
wildtype FO B cell gene expression.  Numbers on the plot represent the number of differentially 
expressed transcripts in each quadrant.  Zfp36l1 has been removed from this analysis.  (b) 
Correlation dot plot indicating the differentially expressed transcripts in red (padj<0.01) when 
comparing Rosa26GFPZFP36L1CD23cre/+ (GFP) FO B cells and Rosa26GFPZFP36L1 control FO B 
cells to wild-type MZ B cell gene expression.  Numbers on the plot represent the number of 
differentially expressed transcripts in each quadrant.  (c) Correlation dot plot showing the 
relationship between the differentially expressed (padj<0.05) genes (red) found in RNAseq 
analysis comparing MZ B cells from Zfp36l1fl/flERT2cre/+ to ERT2cre/+ controls and RNAseq 
analysis comparing GFP-ZFP36L1 positive FO B cells to FO B cells from littermate controls.  
Numbers on the plot represent the number of differentially expressed transcripts in each 
quadrant.  (d) Expression of “MZ-like” surface markers on FO and MZ B cells from 
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Rosa26GFPZFP36L1CD23cre/+ mice and Rosa26GFPZFP36L1 littermate controls.  (e) Calcium flux in 
MZ B cells and FO B cells following stimulation with anti-IgM.  (f) Anti-IgM induced calcium 
flux in MZ and FO B cells following pre-treatment with 10mM EGTA.  Black lines indicate 
Zfp36l1fl/flmb1cre/+ B cells; grey lines indicate Zfp36l1fl/fl B cells from littermate control mice.  
Data are representative of 3 independent experiments (n=3). 
 
Figure 6: ZFP36L1 regulates IRF8 expression 
Normalised read counts for Irf8 in (a) MZ B cells from tamoxifen treated mice, which are 
ERT2cre/+ or Zfp36l1fl/flERT2cre/+, and (b) FO B cells which are Rosa26GFPZFP36L1 or 
Rosa26GFPZFP36L1CD23cre/+.  Error bars represent SEM (n=4).  (c) IRF8 protein expression in 
MZ B cells from Zfp36l1fl/flmb1cre/+ conditional knockout mice (black line) and Zfp36l1fl/fl control 
mice (grey filled histogram).  A representative of at least 7 mice is shown.  (d) Summarised 
FACS analysis showing IRF8 protein expression in MZ B cells from Zfp36l1fl/flmb1cre/+ 
conditional knockout mice and Zfp36l1fl/fl control mice.  Data is pooled from two separate 
experiments, and analysed using a Mann-Whitney test.  (e) Conservation of TATTTATTTTT 
sequence in the 3’UTR of Irf8 (yellow box) in eutherian mammals.  Asterisks denote 100% 
conservation between all species analysed.  Sequences were aligned using ClustalW in 
Ensembl Perl API.  Single nucleotide resolution binding of ZFP36L1 denoted by iCLIP analysis 
is shown as a blue box.  (f) Correlation dot plot as in (Fig. 5a), showing IRF8 targets in green, 
which are differentially expressed in our data (dark green) or are not differentially expressed 
in our data (pale green).  (g) Correlation dot plot as in f, showing iCLIP targets in black, which 
are differentially expressed in our data (black) or are not differentially expressed in our data 
(dark grey). 
 
Figure 7: ZFP36L1 regulates KLF2  
(a) Normalised read counts for Klf2 in MZ B cells from tamoxifen treated mice, which are 
ERT2cre/+ or Zfp36l1fl/flERT2cre/+.  Error bars represent SEM (n=4).  (b) KLF2 protein expression 
in MZ B cells from Zfp36l1fl/flmb1cre/+ conditional knockout chimeras (black line) and Zfp36l1fl/fl 
control chimeras (grey filled histogram).  A representative of at least seven mice is shown.  (c) 
Summarised FACS analysis showing KLF2 protein expression in MZ B cells from tamoxifen 
treated ERT2cre/+ and Zfp36l1fl/flERT2cre/+ mice.  Data were analysed using a Mann-Whitney 
test.  (d) Conservation of TATTTATT sequence in the 3’UTR of Klf2 (yellow box) in mammals 
which express KLF2.  Asterisks denote 100% conservation between all species analysed.  
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Sequences were aligned using ClustalW in Ensembl Perl API.  Single nucleotide resolution 
binding of ZFP36L1 indicated by iCLIP analysis is shown as a blue box.  (e) Correlation dot 
plot as in (Fig. 5a), showing B cell specific KLF2 targets in blue, which are differentially 
expressed in our RNAseq data (dark blue), or are not differentially expressed in our RNAseq 
data (pale blue).  (f) Zoomed in correlation dot plot as in (Fig. 5a), showing B cell specific 
KLF2 targets in blue, IRF8 targets in green, ZFP36L1 direct targets identified by iCLIP analysis 
in cyan, and co-regulated targets (any gene that is identified in at least two datasets) in 
burgundy.  
 
Figure 8: ZFP36L1 controls MZ B cell localization in the splenic MZ 
(a) Expression of trafficking molecules in Zfp36l1 cKO and wildtype MZ B cells, and GFP-
ZFP36L1 positive and negative FO B cells.  A summary of five mice per genotype is shown.  
(b) Capture of PE-conjugated CD19 by MZ B cells in tamoxifen treated Zfp36l1fl/flERT2cre/+ 
mice and ERT2fl/fl controls.  Data were analysed using a Mann-Whitney test.  (c) 
Immunofluorescence analysis of splenic sections from tamoxifen treated Zfp36l1fl/flERT2cre/+ 
mice and ERT2fl/fl μMT chimeras.  Sections were stained with anti-CD1d (magenta), anti-IgD 
(cyan) and anti-CD169 (green).  All images were captured at 20x magnification, error bars 
shown.  CD1d MFI (-background) was calculated using Image-J (NIH) (d) within follicles 
(defined by MOMA-1 staining, see Supplementary Fig. 8e), (e) within MZ area (defined by 
CD1d staining outside of MOMA-1 and IgD staining, see Supplementary Fig. 8e), (f) 
Normalised MFI from within follicles/(MFI MZ + MFI FO). 
 
Supplementary Figure 1: Targeting strategy for the generation of Zfp36fl/fl mice  
(a) The Zfp36 gene consists of two exons (grey boxes).  The targeting vector was designed to 
introduce loxP sites flanking exon 2, which contains the tandem zinc finger RNA binding 
domain, and a Neomycin selection cassette (neo) flanked by two FRT sites.  The targeting 
construct was introduced into the Zfp36 locus of BRUCE4 embryonic stem cells (C57BL/6 
origin) by homologous recombination.  Positive clones were identified via Southern blotting 
confirming correct targeting at both 5’ and 3’ ends.  Subsequent crossing of mice possessing 
the targeted allele to FlpE mice, removing the neo cassette generated the desired Zfp36fl/fl 
mice.  The same gene targeting strategy was used to produce Zfp36l1fl/fl and Zfp36l2fl/fl mice 
(b) Introduction of the hCD2-iCre transgene into homozygous Zfp36fl/fl mice caused a tissue 
specific deletion of exon 2, which was confirmed by Southern blotting. 
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Supplementary figure 2: Peritoneal cavity B1 require ZFP36L1 and GFP-ZFP36L1 fusion 
protein is expressed from the transitional 2 B cell stage in Rosa26GFPZFP36L1CD23cre/+mice 
Flow cytometric analysis of peritoneal cavity B cells from Zfp36l1fl/flmb1cre/+ and Zfp36l1fl/fl mice.  
Dot plots are pre-gated (d) B220intCD19hi cells. Numbers indicate the percentage of cells within 
the gate.  Data are representative of at least 8 mice per genotype.  Absolute number of (b) 
total B1 cells (c) B2 cells (e) B1a cells (f) B1b cells assessed by flow cytometry.  Data on all 
graphs were analysed using a Mann-Whitney test.  (g) Flow cytometric analysis of GFP-
ZFP36L1 fusion protein expression in splenic B cell subsets from 
Rosa26GFPZFP36L1CD23cre/+mice.  Black lines are representative of GFP-ZFP36L1 expression 
in Rosa26GFPZFP36L1CD23cre/+ mice; grey filled histograms are representative of cre-negative 
littermate control mice.  
 
Supplementary figure 3: MZ B cells require ZFP36L1 to persist over time 
(a, d, g) Relative Zfp36l1 exon 2 abundance in purified B cells assessed by qPCR in tamoxifen 
treated Zfp36l1fl/flERT2cre/+ and ERT2cre/+ mice.  Absolute numbers of (b, e, h) MZ B cells (c, f, 
i) FO B cells assessed by flow cytometry in tamoxifen treated mice.  Data were analysed with 
a Mann-Whitney test.  Panels a, b and c show analysis on day 7 following start of tamoxifen 
treatment, d, e and f show day 10 and g, h and i show day 14.  
 
Supplementary figure 4: ZFP36L1 controls turnover of MZ B cells 
(a) Day 14 BrdU incorporation into splenic B cell subsets in Zfp36lfl/flmb1cre/+ conditional 
knockout mice (open circles) and Zfp36l1fl/fl littermate control mice (closed circles) (b) Day 14 
BrdU incorporation into splenic B cell subsets from Rosa26GFPZFP36L1CD23cre/+ and 
Rosa26GFPZFP36L1 littermate control mice.  
 
Supplementary figure 5: RNAseq analysis validation 
(a) Reads mapping to Zfp36l1.  Reads were mapped using TopHat, and are displayed using 
IGV.  Enrichment of uniquely aligning deduplicated reads shown in grey.  The top 4 rows show 
reads in control (ERT2cre/+) replicates, and the bottom 4 rows show reads in KO 
(Zfp36l1fl/flERT2cre/+) replicates.  (b) Normalised read counts for Zfp36 and Zfp36l2 in MZ B 
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cells from tamoxifen treated mice which are ERT2cre/+ (black bars) or Zfp36l1fl/flERT2cre/+ (white 
bars).  Error bars represent SEM (n=4).  
 
Supplementary figure 6: Heatmap illustrating the top 50 regulated genes in 
Zfp36l1fl/flERT2cre/+ MZ B cells compared to ERT2cre/+ controls 
A clustered heatmap showing the log2 transformed RPKM values of 50 most regulated genes 
based on their log2FoldChange in the comparison of Zfp36l1fl/flERT2cre/+ MZ B cells to their 
ERT2cre/+ controls.  Blue color indicates low, yellow medium and red high expressed genes.  
Dendrogram shows clustering of the genotypes.  
 
Supplementary figure 7: Normal p27 and Ki67 expression and DAPI profiles in Zfp36l1-
deficient MZ B cells 
(a) p27 staining in MZ B cells from Zfp36l1fl/flmb1cre/+ mice (black line) and Zfp36l1fl/fl littermate 
controls (grey filled histogram) (left panel) and tamoxifen treated Zfp36l1fl/flERT2cre/+ (black 
line) and ERT2cre/+ control chimeras (grey filled histogram) (right panel).  Isotype control 
sample (grey line) is shown for both sets of analysis.  Summarised analysis showing the 
proportion of p27+ MZ B cells in (b) Zfp36l1fl/fl and Zfp36l1fl/flmb1cre/+ mice, (c) ERT2cre/+ and 
Zfp36l1fl/flERT2cre/+ chimeric mice.  Data were analysed using a Mann-Whitney test.  (d) Ki67 
staining in MZ, FO and GC B cells from Zfp36l1fl/flmb1cre/+ mice (black line) and Zfp36l1fl/fl 
littermate controls (grey filled histogram).  FMO control sample (grey line) is shown for all sets 
of analysis.  (e) Summarised analysis showing the proportion of Ki67+ cells in Zfp36l1fl/flmb1cre/+ 
mice (filled circles) and Zfp36l1fl/fl mice (open circles). Data were analysed using a Mann-
Whitney test.  (g) DAPI staining in MZ and FO B cells from Zfp36l1fl/flmb1cre/+ mice and 
Zfp36l1fl/fl littermate controls.  Numbers on the graph indicate the percentage of cells in the 
gate.  Summarised analysis showing the proportion of cells in the S/G2-M phase of the cell 
cycle in (h) MZ and (i) FO B cells.  Data were analysed using a Mann-Whitney test.  
 
Supplementary figure 8: ZFP36L1 regulates localisation, identity and survival 
(a) Immunofluorescence analysis of spleen sections from Zfp36l1fl/flCD23cre/+ mice, 
Rosa26GFPZFP36L1CD23cre/+ mice.  Sections were stained with anti-CD1d (red) and anti-IgD 
(green).  Images were captured at 20x magnification, scale bars are shown.  Arrows on the 
plots indicate colocalization of the stains, or single stained cells only.  (b) Day 4 NP-specific 
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IgM endpoint titres from mice immunized with NP-α-GalCer.  Data were analysed using a 
Mann-Whitney test.  (c) Schematic model depicting the mechanism by which ZFP36L1 
regulates survival, migration and identity of MZ B cells through a network of transcription 
factors which include KLF2 and IRF8. 
Supplementary figure 9: ZFP36L1 controls genes involved in mature B cell trafficking 
(a) Venn diagram indicating the number of overlapping genes, which are increased in Zfp36l1-
deficient MZ B cells, and decreased in GFP-ZFP36L1 expressing FO B cells using a padj<0.05 
cutoff.  (b) Pathway analysis of genes which are increased in expression in Zfp36l1 cKO MZ 
B cells and decreased in expression in GFP-ZFP36L1 expressing FO B cells using a 
padj<0.05 cutoff.  S1pr1 mRNA expression in (c) Zfp36l1fl/flERT2cre/+ MZ B cells and ERT2cre/+ 
control MZ B cells, and (d) Rosa26GFPZFP36L1CD23cre/+ and Rosa26GFPZFP36L1 FO B cells.  (e) 
Follicular area was defined using MOMA-1 (CD169) staining (green).  Follicular area is shown 
by yellow line.  MFI was then calculated for this area.  MZ area was defined as CD1d+ 
(magenta) area outside MOMA-1 (green) and IgD (not shown) staining.  MZ area is shown by 
white line.  Background fluorescence (grey box) was calculated and subtracted from MFI.  
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MATERIALS AND METHODS 
Reagents, antibodies and oligonucleotides.  This information is provided in 
Supplementary Tables 7 (reagents), 8 (antibodies) and 9 (oligonucleotides).  
 
Mouse strains and animal procedures.  Mice on the C57BL/6 background used in this study 
were derivatives of the following: Tg(CD2-cre)4Kio28, CD79atm1(cre)Reth58, Tg(Fcer2a-
cre)5Mbu29, Gt(ROSA)26Sortm1(cre/ERT2)Thl 59, Zfp36tm1Tnr (Supplementary Fig. 1), 
Zfp36l1tm1.1Tnr26, Zfp36l2tm1.1Tnr26, Gt(Rosa)26Sortm1(GFPZfp36l1)Tnr 27, B6.129S1-Bcl2l11tm1.1Ast/J60. 
All mice were aged between 8-12 weeks.  B6.SJL mice, which were used in competitive bone 
marrow chimera experiments, are Ly5.1 (CD45.1 allotype) C57BL/6 congenic mice obtained 
from Jackson labs, USA.  For bone marrow chimeras, B6.SJL recipient mice were irradiated 
and reconstituted with a total of 3x106 donor bone marrow cells by i.v. injection.  Reconstituted 
mice were fed neomycin sulphate (Sigma) in their drinking water for four weeks post-
reconstitution, and were analysed after 8-10 weeks.  In the case of μMT chimeras, of the 3x106 
donor BM cells, 80% were taken from μMT mice, and 20% from either Zfp36l1fl/flERT2cre/+ or 
ERT2cre/+controls. BrdU (Sigma) was administered at 0.8mg/ml in drinking water.  Unless 
otherwise stated, control mice used in experiments were littermate controls that were negative 
for Cre.  Tamoxifen (Cambridge Bioscience Ltd.) was prepared in sunflower oil containing 10% 
ethanol to a final concentration of 50mg/ml.  Daily dosage for mice was 200mg/kg.  Tamoxifen 
was fed to mice for two consecutive days using a bulb-tipped reusable feeding needle.  After 
induction of cre, mice were returned to stock and euthanized at the appropriate time point.  
0.8μg of PE-labelled anti-mouse CD19 antibody in PBS was administered intravenously and 
mice were culled at 5 minutes following injection.  Spleen cell suspensions were prepared and 
surface stained as described.  The Animal Welfare and Experimentation Committee of 
Babraham Institute and the UK Home Office approved all animal procedures at the Babraham 
Institute. 
Flow cytometry.  B cell populations were analysed using antibodies against B220, CD19, 
CD21, CD23, CD93, IgD and IgM (Supplementary table 8).  B cells analysed in the bone 
marrow were as follows: Immature B cells, B220+IgM+IgD-; Recirculating B cells, B220+IgM-
IgD+.  B cells analysed in the spleen were as follows: T1 B cells, B220+CD93+CD23−IgMhi; T2 
B cells, B220+CD93+CD23+IgMhi; T3 B cells, B220+CD93+CD23+IgM+; marginal zone 
precursors, B220+CD93+CD21hiIgMhi; marginal zone B cells, B220+CD93-CD21hiCD23− or 
B220+CD9+CD1dhi and follicular B cells, B220+CD93-CD21+CD23+.  Fixable viability dye 
eFluor780 was used to assess cell viability.  BrdU was detected using the BrdU flow kit (BD), 
following the manufacturer’s instructions.  Cells were analysed using a BD LSRFortessa flow 
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cytometer.  To measure apoptosis, 5x106 cells were stained intracellularly with a FITC 
conjugated rabbit monoclonal antibody, which recognises active Caspase-3 (BD Biosciences). 
Calcium flux analysis.  Splenocytes were loaded for 30min at 37⁰C in the dark with 0.6µM 
Ca2+ indicator PBX (BD) in serum free DMEM (5-10x106 cells).  Cells were then stained with 
surface antibodies at RT, and resuspended in serum free Hanks medium.  Cells were pre-
treated with 10mM EGTA for 1 minute if required, before being stimulated with 10μg/ml goat 
polyclonal α-IgM F'ab fragment (Jackson ImmunoResearch).  Fluorescence emission (525nm) 
was measured using a 488nm laser and 530/30 filter on a BD LSRFortessa flow cytometer.  
B cell purification and sorting.  B cells from spleen or peripheral lymph nodes were isolated 
with a B cell Isolation Kit from Miltenyi Biotech.  To purify specific B cell subsets, cells were 
subsequently sorted using a BD FACSAria III or a BD FACSAria Fusion, using staining 
described above. 
DNA isolation, RNA extraction and RT-qPCR assays.  Total RNA was extracted from 
purified B cells using TRIzol (LifeTech) or RNeasy Micro or Mini Kit (Qiagen).  RNA was treated 
with DNase I before reverse transcription into cDNA.  ZFP36 family expression was analysed 
using custom and commercially available TaqMan assays with specific primers 
(Supplementary Table 9).  Expression of mRNA was calculated using a standard curve and 
normalised to the expression of β2M.  Genomic DNA was extracted from purified B cells using 
Cell lysis solution (Qiagen) containing proteinase K (Roche).  Protein was removed by salt 
precipitation, and the DNA was isolated using isopropanol.  Relative abundance of ZFP36l1 
exon 2 was analysed by quantitative PCR with specific primers (Supplementary Table 9), 
qPCR assays were performed with Platinum SYBR Green qPCR SuperMix (Life 
Technologies).  Relative abundance of ZFP36l1 was calculated using the comparative 
threshold cycle (ΔΔCT) method and results were normalised to the expression of TBP. 
 
Immunofluorescence.  Spleens were frozen in OCT compound on dry-ice, and sectioned on 
the cryostat (7-10µm thick).  Sections were air dried overnight, then fixed in ice cold acetone 
for 15 mins at 4˚C.  Tissue sections were rehydrated in PBS for 10, and blocked in 5% NRS. 
Sections were stained in 5% NRS at 4˚C overnight in a humidified chamber to detect IgM and 
MOMA-1, or CD1d, IgD and MOMA-1. Slides were washed PBS, and mounted in ProLong 
Gold antifade reagent (Thermo Fischer).  Images were acquired at x10 or ×20 magnification 
using a DeltaVision widefield fluorescence microscope (GE Healthcare).  Images were 
quantified using Image-J software (NIH).  MZ width was measured using Image-J software.  
At least 10 follicles per genotype were imaged, measurements were taken from the edge of 
MOMA-1+ cells to the edge of CD1d+ staining.  A number of measurements were taken per 
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follicle to account for variability.  CD1d MFI (-background) was calculated using Image-J (NIH).  
Follicular area was defined using MOMA-1 (CD169) staining.  MFI was then calculated for this 
area (see Supplementary Fig. 8e).  MZ area was defined as CD1d+ area outside MOMA-1 
and IgD staining (see Supplementary Fig. 8e).  Background fluorescence was calculated and 
subtracted from MFI values for MZ and FO.  Measurements were taken from 10 follicles from 
2 ERT2cre/+ chimeras, and 25 follicles from 2 Zfp36l1fl/flERT2cre/+ chimeras.  
Library preparation and high-throughput sequencing.  Sorted MZ or FO B cells from 
individual control mice were independently processed for RNA extraction.  RNAseq libraries 
were obtained using a TruSeq Stranded mRNA Sample Prep Kit (Illumina) or SMARTer Ultra 
Low Input RNA v4 and SMARTer Low Input Library Prep Kit V2 (Clontech).  Low input libraries 
were prepared and sequenced from total RNA at Aros Applied Biotechnology A/S. RNAseq 
libraries were sequenced using the HTSeq2000 (Illumina).  100bp single end or paired end 
sequencing was performed on all libraries.   
Bioinformatics for RNAseq.  Quality of sequencing data was analysed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Reads were mapped to mouse 
genome (GRCm38) using Tophat261.  Reads aligning to genes were counted using htseq-
count62 and analysis of differentially expressed genes was performed using the DESeq2 
(R/bioconductor package)63.  Reads were visualised using Integrative Genomics Viewer 
(IGV)64, 65.  Gene set enrichment analysis was performed using ToppGene66 and the enriched 
GO biological processes were visualised using Revigo57.  iCLIP data was analysed as 
previously described27.  
To analyse conservation of Zfp36l1 binding motif in its target genes, the 3’UTR sequence of 
selected gene in mouse was queried against synthenic sequences in eutherian mammals 
using Ensembl Perl API. 
Bioinformatics for publically available data.  ChIP-seq data for Klf237 and IRF835 and 
Affymetrix data for Klf2-deficient FO B cells14 were downloaded from the Gene Expression 
Omnibus.  The Affymetrix data was analysed using R/Bioconductor package affy67.  Reads 
from ChIP-seq data were mapped to mouse genome (GRCm38) using Bowtie268 and peaks 
were called using MACS269.  Only reproducible peaks were considered.  Peaks were 
visualised using IGV. 
Statistical analysis.  Mann-Whitney tests were performed for statistical analysis of non-
sequencing data.  Additional details regarding sample size and statistics used have been 
provided in the figure legends where relevant.  
27 
Accession number.  The RNA-seq data are available in the Gene Expression Omnibus 
(GEO) database (http://www.ncbi.nlm.nih.gov/gds) under the accession number: GSE79632. 
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Supplementary table 1: Differentially expressed genes in Figure 4A 
Differentially expressed genes (padj<0.01) when comparing MZ B cells from tamoxifen treated 
Zfp36l1fl/flERT2cre/+ and ERT2cre/+ mice.  A 1.5 fold change cut-off has been applied.   
Supplementary table 2: Up regulated genes (padj<0.01) for GSEA showing iCLIP hits 
and AREs 
Genes that are increased in expression (padj<0.01) when comparing MZ B cells from 
tamoxifen treated Zfp36l1fl/flERT2cre/+ and ERT2cre/+ mice.  Hits in iCLIP analysis and ARE 
found in the 3’UTR of the gene are indicated.  An FDR rate of 0.05 was used for the iCLIP 
data. 
Supplementary table 3: Down regulated genes (padj<0.01) for GSEA showing iCLIP hits 
and AREs 
Genes that are decreased in expression (padj<0.01) when comparing MZ B cells from 
tamoxifen treated Zfp36l1fl/flERT2cre/+ and ERT2cre/+ mice.  Hits in iCLIP analysis and ARE 
found in the 3’UTR of the gene are indicated.  An FDR rate of 0.05 was used for the iCLIP 
data. 
Supplementary table 4: Differentially expressed genes in Figure 5A 
Differentially expressed genes (padj<0.01, and subject to a 1.5 fold cut-off) when comparing 
Zfp36l1fl/flERT2cre/+ (KO) MZ B cells and ERT2cre/+ control (WT) MZ B cells to wildtype FO B 
cell gene expression.  Gene lists have been separated into each quadrant of the correlation 
dot plot.  Zfp36l1 has been removed from this analysis.   
Supplementary table 5: Differentially expressed genes in Figure 5B 
Differentially expressed genes (padj<0.01, and subject to a 1.5 fold cut-off) when comparing 
Rosa26GFPZFP36L1CD23cre/+ (GFP) FO B cells and Rosa26GFPZFP36L1 control FO B cells to 
wildtype MZ B cell gene expression.  Gene lists have been separated into each quadrant of 
the correlation dot plot.  Zfp36l1 has been removed from this analysis.   
Supplementary table 6: Differentially expressed genes in Figure 5C 
Differentially expressed genes (padj<0.05) found in RNAseq analysis comparing MZ B cells 
from Zfp36l1fl/flERT2cre/+ to ERT2cre/+ controls and RNAseq analysis comparing GFP-ZFP36L1 
positive FO B cells to FO B cells from littermate controls.  Gene lists have been separated into 
each quadrant of the correlation dot plot.  Zfp36l1 has been removed from this analysis.    
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Supplementary table 7: List of reagents 
Reagent Source Cat. Number Application 
B cell Isolation Kit Miltenyi Biotec 130-090-862 B cell isolation 
DMEM Life Tech 41965 Calcium flux 
Hanks Medium Sigma Aldrich H6648 Calcium flux 
PBX Calcium Assay kit BD Biosciences 640175 Calcium flux 
Fixable Viability Dye eFluor® 780 eBioscience 65-0865-14 FC 
BD Cytofix/CytopermTM BD Biosciences 554714 FC 
FITC BrdU Flow Kit BD Biosciences 559619 BrdU Assay 
APC BrdU Flow Kit BD Biosciences 552598 BrdU Assay 
5-bromo-2-deoxyuridine Sigma Aldrich B-5002 BrdU Assay 
Dimethyl sulfoxide Sigma Aldrich D2650 - 
TRIzol® Reagent Life Tech 15596-026 RNA  
RNeasy Micro Kit Qiagen 74004 RNA  
RNeasy Mini Kit Qiagen 74106 RNA  
RNase free DNase Qiagen 79254 RNA  
Platinum® SYBR® Green qPCR 
SuperMix-UDG w/ROX 
Life Tech 11744 qPCR 
TruSeq Stranded mRNA Sample Prep 
Kit 
Illumina RS-122-2103 RNAseq 
SMART-Seq v4 Ultra Low Input RNA 
Kit for Sequencing 
Clontech 634888 RNAseq 
SMARTer low input library prep kit v2 Clontech 634899 RNAseq 
Cell lysis solution Qiagen 158908 DNA work 
Protein precipitation solution Qiagen 158910 DNA work 
Tamoxifen Cambridge 
Bioscience 
CAY13258 Tamoxifen 
 
OCT compound Thermo Scientific 12678646 IF 
Prolong Gold Antifade Mountant Thermo Scientific P36934  IF 
Acetone (99.8% for HPLC) Fisher Scientific 10442631 IF 
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Supplementary table 8: List of antibodies 
Antigen Source Isotype (Clone) Application Company 
B220/CD45R Rat IgG2a (RA3-6B2) FC eBioscience 
β7 integrin Rat IgG2a (FIB504) FC Biolegend 
Caspase 3 Rabbit IgG (C92-605) FC BD Bioscience 
CD1d Mouse IgG2b (WTH-2) FC T. Herrmann 
CD1d Rat IgG2b (1B1) IF Biolegend 
CD169 Rat IgG2a (MOMA-1) IF Serotec 
CD19 Rat IgG2a (6D5) FC BioLegend 
CD19 Rat IgG2a (1D3) FC eBioscience 
CD21 Rat IgG2b (7G6) FC BD Pharmingen 
CD21 Rat IgG2a (4E3) FC eBioscience 
CD23 Rat IgG2a (B3B4) FC BD Pharmingen 
CD45.2 Mouse IgG2a (104) FC eBioscience 
CD62L Rat IgG2a (MEL-14) FC eBioscience 
CD93 Rat IgG2b (AA4.1) FC eBioscience 
IgD Rat IgG2a (11-26) FC eBioscience 
IgD Rat IgG2a (11-26c.2a) IF Biolegend 
IgM Rat IgG2a (R6-60.2) FC BD Biosciences 
IgM Goat Whole IgG  IF Jackson 
ImmunoResearch 
IgM – F(ab)2 Goat Mouse specific Cell 
activation  
Jackson 
ImmunoResearch 
KLF2 Mouse IgG2b (665333) FC R&D Systems 
MHC-II (I-A/I-E) Rat IgG2b 
(M5/114.15.2) 
FC eBiosciences 
P27 Rabbit IgG (Y236) FC Abcam 
Rabbit Ig Goat Rabbit specific FC Jackson 
ImmunoResearch 
Rabbit Ig Goat Rabbit specific FC Molecular Probes 
ZFP36l1 
(BRF1/2) 
Rabbit Polyclonal iCLIP Cell Signaling 
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Supplementary table 9: List of primers and Taqman assays for RT-qPCR 
Primer pair name Sequence Comment 
TBP (fwd) GAATCGGTTTCCCAAATACTCAG Normalisation 
TBP (rev) CAATCTTAAAATCGCAATAATCGC 
ZFP36l1 exon 2 (fwd) CCTATCAGATGGAGAGGTGCTGTC Deletion efficiency 
ZFP36l1 exon 2 (rev) TGTAGTTGAGCATCTTGTTACCCTGG 
 
Commercially available Taqman assays 
 
Taqman assay name Assay ID Comment 
Β2M Mm00437762_m1 Normalisation 
ZFP36 Mm00457144_m1 Transcript abundance 
 
Custom Taqman assays 
Primer 
pair 
name 
Sequence Comment Probe Sequence 
ZFP36l1 
(fwd) 
CTTCACGACACACCAGATCCTAGT Transcript 
abundance 
(FAM) 
AACGCCCACGATGA 
(MGB) ZFP36l1 
(rev) 
TGCTGTAGTTGAGCATCTTGTTACC 
ZFP36l2 
(fwd) 
ATGTCGACCACACTTCTGTCACC Transcript 
abundance 
(FAM) 
AGGGATTTCTCCGTCT
TGC ZFP36l2 
(rev) 
CTTCTTGTCCAGCATGTTGTTCAG 
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Mouse 8:120755170-120756700 CTAGTGT---------------CCAAATATTTATTTTTGTATTCTCTTAAGAAGTAT----
Cow 18:11904197-11921287 -TAATATGCTGA----------AA----AACTATTTTTGATTTCATTAAAA-AGTTTACTA
Dog 5:66789257-66791355 -GAATATGCTAA----------ATGAATATTTATTTTTGTATCCATTTAAAATGTATA---
Horse 3:32873474-32875681 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTTAAGAAATATG---
Green Monkey 5:71324280-71325628 -TAATATGCTGA----------ATGAATATTTATTTTTGCATCCATTT--ACAGTATA---
Rhesus Macaque 20:84072219-84073569 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTT--ACAGTATA---
Olive Baboon 20:67654959-67656621 -TAATATGCTGA----------ATGAATATTTATTTTTGTACCCATTT--ACAGTATA---
Orangutan 16:73662315-73663670 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTAAAACAGTATA---
Gorilla 16:76499697-76501051 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTAAAACAGTGTA---
Human 16:85921277-85922613 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTAAAACAGTATA---
Chimpanzee 16:85584657-85586011 -TAATATGCTGA----------ATGAATATTTATTTTTGTATCCATTAAAACAGTATA---
Marmoset 20:40326666-40328352 -TAATATGCTGA----------GTGAATATTTATTTTTGTATCCATTAAAACGGTATA---
Rat 19:65053991-65055536 CAAGTGTGCCCAACTCTGTAATCCAAATATTTATTTTTGTATTCACTTAAAAAGTAT----
Rabbit GL019024:192070-193370 -CACCGTGCCGA----------GC-GGTATTTATTTTTGTAGCAGTTTTAAAAGTATC---
*  .*                     *: ******** : .   *:  .  .* * 
ARE: TATTTATTTTT 
iCLIP: TATTTATTTTT
padj=1.9x10-4 
padj=0.0015 
IRF8 targets iCLIP targets 
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